Suggestions
Alex Menys
CEO at Motilent | Ph.D and Honorary Associate Prof. at UCL
Alex Menys is a dedicated professional with a primary focus on measuring treatment response in Crohn's Disease and is actively engaged in diverse gastro-related projects, encompassing conditions like constipation, gastroparesis, IBS, and other gastrointestinal diseases.
He is particularly enthusiastic about the advancements in non-invasive gastroenterology utilizing technologies such as MRI, ultrasound, and capsule endoscopy. Alex Menys is the founder of Motilent, a platform aimed at bridging the gap between technology and healthcare, while maintaining a profound interest in collaborative research efforts with global partners.
His core beliefs revolve around the significance of Real World Evidence in evaluating new technologies, understanding healthcare processes before implementing innovations, acknowledging that change in healthcare requires close collaboration with professionals, and recognizing that innovation and adoption in healthcare are long-term endeavors.
Alex Menys is a highly qualified individual, holding a Doctor of Philosophy (PhD) in MR Physiology, with a specialization in Medical Image Computing and Medical image post-processing, along with studies in Experimental Medicine focusing on Antibody engineering, and a background in Biochemistry from UCL and King's College London.
With a rich professional background, Alex Menys has served in various roles including as a Former Honorary Associate Professor at UCL, Former CEO at Motilent, Former Non Executive Director at FEEDBACK PLC, and as a Former Postdoctoral Fellow at UCL.
Highlights
Gastroparesis - the chronic feeling of bloating, nausea and upper GI discomfort. With GLP1 helping to boost the prevalence to 1-2% of the population, is it finally getting the attention it deserves? Let’s take a closer look for Gastroparesis awareness month. The stomach is a complex system that senses, stretches and breaks down our food chemically and mechanically. It carefully expands to ‘accommodate our meal’ before stretch receptors say ‘stop we’re full!’ It’ll signal to the small bowel and colon while communicating back and forth with the brain. It’s all got to work correctly.
Imagine an orchestra, all the players need to be doing their part for the performance to sound right. One rogue tuba and you have a farce on your hands. But how can you identify the wrong thing happening if you’re watching the performance on the TV with the sound off?
Here are my key takeaways for gastroparesis awareness month, we need:
📈 Better, holistic testing of gut health - The central dogma of gastroparesis is the presence of ‘delayed gastric emptying’ basically the only thing we can measure routinely in clinic. High inter-patient variability, (gastroparesis one week, functional dyspepsia the next and inseparable from a healthy control a month later) is one of the major challenges we need to overcome. A battery of tests measuring accommodation, contractility, pyloric function etc is almost certainly needed to phenotype patients. At the moment, we’re watching that person with the gong in the percussion section.
🎯 Objective trial endpoints - the FDA have recently dropped our one test, gastric emptying, as a primary and secondary endpoint moving entirely towards patient reported outcomes (PRO). Symptoms are crucial but without knowing what’s driving, for example, ‘fullness,’ patient selection and proof of efficacy is extremely challenging.
🧘 Treat the patient not the symptoms: The brain and gut-brain axis have probably as much to do with symptoms as the gut itself. We need more input from allied specialties (e.g psychology and psychiatry) to complement gastric tests and support PRO development. If the orchestra’s not watching the conductor, they can end up playing the wrong concerto beautifully.
There are few quick wins in modern medicine. Most of our healthcare burden today lies in complex, chronic diseases that lie outside of any one specialty. My orchestra metaphor is now stretched thin but we’re not looking at ‘solos’ anymore, we’re watching at the whole performance. We should scrap the name Gastroparesis, share ideas openly and be willing to go back to the start where necessary to enable science based management of what we should start calling ‘disorders of gastric physiology.’
#gastroparesis #gastroparesisawarenessmonth
Midway through the Motilent trip to Florida! Great to see not one but four studies featuring #GIQuant and #GISeg in pediatric #CrohnsDisease at #SPR24 ✅. In summary, bowel physiology (motility, measured with #GIQuant) revealing added information beyond structural imaging alone, especially in #fibrostenotic disease. Huge thanks to our collaborators at MasGen, GOSH and Cincinnati.
Now onto #SAR24 for even more focused discussions on GI imaging in this amazing location!
